EnVivo Pharmaceuticals Initiates Cognitiv Ad, a Phase 3 Clinical...

EnVivo Pharmaceuticals , a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 potentiator, encenicline-hydrochloride , in patients with Alzheimer's disease .

http://ift.tt/1fZSLTo